Journal
CANCER CELL
Volume 28, Issue 6, Pages 687-689Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2015.11.010
Keywords
-
Categories
Funding
- Wellcome Trust [095688] Funding Source: Medline
- Wellcome Trust [095688/Z/11/Z] Funding Source: Wellcome Trust
- BBSRC [BB/I005609/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/I005609/1] Funding Source: researchfish
- Wellcome Trust [095688/Z/11/Z] Funding Source: researchfish
Ask authors/readers for more resources
Gut microbes have ascended to prominence as key modulators of host immunity, raising the possibility that they could influence the outcome of cancer immunotherapy. Two recent studies address this question by identifying specific gut-resident bacteria as drivers of checkpoint blockade immunotherapy in pre-clinical tumor models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
